Ocular Therapeutix (OCUL) Gains from Sales and Divestitures (2015 - 2025)

Ocular Therapeutix's Gains from Sales and Divestitures history runs 4 years deep, the most recent figure standing at $1.6 million for Q4 2025.

• In Q4 2025, Gains from Sales and Divestitures rose 21.47% year-over-year to $1.6 million; the TTM figure through Dec 2025 stood at $1.6 million (up 21.47% YoY), while the FY2025 annual figure was $1.6 million, up 21.47% from the prior year.
• Gains from Sales and Divestitures was $1.6 million for Q4 2025 at Ocular Therapeutix, up from $1.3 million in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $1.6 million in Q4 2025 to a low of $393805.0 in Q4 2023.
• Historically, Gains from Sales and Divestitures has averaged $1.1 million across 3 years, with a median of $1.3 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Gains from Sales and Divestitures soared 224.37% in 2024, then rose 21.47% in 2025.
• A 3-year view of Gains from Sales and Divestitures shows it stood at $393805.0 in 2023, then jumped by 224.37% to $1.3 million in 2024, then climbed by 21.47% to $1.6 million in 2025.
• The last three Gains from Sales and Divestitures figures came in at $1.6 million (Q4 2025), $1.3 million (Q4 2024), and $393805.0 (Q4 2023), per Business Quant data.